Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

详细信息    查看全文

• 作者：Masao Omata ; Tatsuo Kanda ; Osamu Yokosuka ; Darrell Crawford…
• 关键词：Asian Pacific countries ; HCV ; IL28B ; Direct ; acting antivirals
• 刊名：Hepatology International
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：9
• 期：4
• 页码：486-507
• 全文大小：796 KB
• 参考文献：1.Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(1 Suppl):S58–S68PubMed
  2.Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA. 1990;87:6547-549PubMedCentral PubMed
  3.Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31(Suppl 2):61-0PubMed
  4.Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010;4:548-61PubMedCentral PubMed
  5.Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-61PubMed
  6.Yu ML, Dai CY, Lin ZY, Lee LP, Hou NJ, Hsieh MY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006;26:73-1PubMed
  7.Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012;56:78-4PubMed
  8.Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014;21:762-68PubMed
  9.Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, et al. STARTVerso1: a randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. J Hepatol 2015 Jan 2 (in press)
  10.Dore GJ, Law G, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003;26:171-84PubMed
  11.Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection; genotyping and its clinical role. Future Microbiol 2006;1:103-12PubMed
  12.Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, et al. Distribution of interferon lamda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: analysis from the PREDICT and CHARIOT studies. J Gastroenterol Hepatol 2014;29:179-84PubMed
  13.Kumar D, Wallington-Beddoe C, George J, Lin R, Samarasinghe D, Liddle C, et al. Effectiveness of intereferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Med J Aust 2003;178:267-71PubMed
  14.Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, et al. Impact of high dose peginterferon alpha-2A on virological response rates in hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2009;50:1045-055PubMed
  15.Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-410PubMed
  16.Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Bocepravir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-06PubMedCentral PubMed
  17.Khan M, Husain M, Yano M, Hashizume K, Yousuf M, Tanaka E, et al. Comparison of seroepidemiology of hepatitis C in blood donors between Bangladesh and Japan. Gastroenterol Jpn. 1993;28:28-1PubMed
  18.Akbar SMF, Hossain M, Hossain MF, Sarker S, Hossain SAS, Tanimoto K, et al. Seroepidemiology of hepatitis viruses of chronic liver diseases in Bangladesh: high prevalence of HCV among blood donors and healthy persons. Hepatol Res. 1997;7:113-20
  19.Mahtab MA, Karim F, Foster G, Akbar SMF, Rahman S. Prevalence and risk factors of asymptomatic HCV infection in Bangladesh. J Clin Exp Hepatol 2011;1:13-6
  20.Ashraf H, Alam NH, Rothermundt C, Brooks A, Bardhan P, Hossain L, et al. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis 2010;10:208PubMedCentral PubMed
  21.Rudra S, Chakrabarty P, Poddar B. Prevalence of hepatitis B and hepatitis C virus infection in human of Mymensingh, Bangladesh. Mymensingh Med J 2011;20:183-86PubMed
  22.Rudra S, Chakrabarty P, Hossain MA, Akhter H, Bhuiyan MR. Seroprevalence of Hepatitis B, Hepatitis C, HIV Infections in blood donors of Khulna, Bangladesh. Mymensingh Med J 2010;19:515-19PubMed
  23.Aliberch MRM, Buxó AE, Gil BM, Rodriguez CC, de FrutosGallego E, Molina CG, et al. Indication of determination of antibodies against hepatitis C and A viruses in the protocol for the care of young immigrants. Gac Sanit 2010;24:288-92
  24.Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, et al. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the preval
• 作者单位：Masao Omata (1) (2)
  Tatsuo Kanda (3)
  Osamu Yokosuka (3)
  Darrell Crawford (4)
  Mamun Al-Mahtab (5)
  Lai Wei (6)
  Alaaeldin Ibrahim (7)
  George K. K. Lau (8)
  Barjesh C. Sharma (9)
  Saeed S. Hamid (10)
  Wan-Long Chuang (11)
  A. Kadir Dokmeci (12)
  
  1. Yamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan
  2. University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
  3. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan
  4. University of Queensland, School of Medicine, Woolloongabba, QLD, 4102, Australia
  5. Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh
  6. Peking University People’s Hospital, Peking University Hepatology Institute, Beijing, China
  7. GI/Liver Division, Department of Internal Medicine, University of Benha, Benha, Egypt
  8. Humanity and Health Medical Centre, Hong Kong SAR China Institute of Translational Hepatology and Centre of Liver Fibrosis Diagnosis and Treatment Center, 302 Hospital, Beijing, China
  9. Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India
  10. Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan
  11. Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
  12. Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey
  
• 刊物主题：Hepatology; Colorectal Surgery; Surgery;
• 出版者：Springer India
• ISSN：1936-0541

文摘

Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4-.0, 14.7, 0.1-.3, 0.9-.9, 1.0-.0, 5, 4.4-.6 and 0.5-.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (Gs) are G1, G3, G1b, G4, G1b, G3, G1b, G3, G1b and G2, and G1 in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. Of IL28B genotypes, favorable alleles are ~50 % in Australia and Turkey, but 60-0 % in most of the other Asian countries. Peginterferon plus ribavirin is available in all ten Asian Pasific countries. In addition, HCV NS3/4A protease inhibitors with peginterferon plus ribavirin are currently available in several countries. Clinical trials of interferon-free regimens for HCV are ongoing in most of the ten Asian Pacific countries. Keywords Asian Pacific countries HCV IL28B Direct-acting antivirals